Furthermore, sorafenib enhances TRAIL-induced cell death through SH2 domain-containing tyrosine phosphatase (SHP-1)-dependent reduction of signal transducers and activators of transcription type 3 (STAT3) phosphorylation (Tyr705STAT3) and related proteins Mcl-1 (myeloid cell leukemia 1), survivin, and cyclin D1 in hepatoma cells (Chen et al., 2010). This evidence concerns the gene MCL1 and hepatocellular carcinoma.